Clinical significance and dynamics of biomarkers of myocardial remodeling in patients with ST segment elevation myocardial infarction and preserved left ventricular function
https://doi.org/10.15372/ATER20180101
Abstract
About the Authors
T. B. PecherinaRussian Federation
N. V. Fedorova
Russian Federation
A. I. German
Russian Federation
A. G. Chernobay
Russian Federation
T. P. Solodilova
Russian Federation
V. N. Karetnikova
Russian Federation
O. V. Gruzdeva
Russian Federation
O. M. Polikutina
Russian Federation
V. V. Kashtalap
Russian Federation
O. L. Barbarash
Russian Federation
References
1. Lloyd-Jones D., Adams R., Carnethon M. et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee // Circulation. 2009 Jan 27. Vol. 119, N 3. P. 21-181.
2. Roger V.L., Weston S.A., Redfield M.M. et al. Trends in heart failure incidence and survival in a community-based population // JAMA. 2004 Jul 21. Vol. 292, N 3. P. 344-350.
3. Рекомендации ESC по диагностике и лечению острой и хронической сердечной недостаточности 2016 // Рос. кардиол. журн. 2017. Т. 1 (141). С. 7-81. http://dx.doi.org/10.15829/1560-4071-2017-1-7-81
4. Gazewood J.D., Turner P.L. Heart Failure with Preserved Ejection Fraction: Diagnosis and Management // Am. Fam. Phys. 2017. Nov 1. Vol. 96, N 9. P. 582-588.
5. Tromp J., Mohsin A.F.K., IJsbrand T.K. et al. Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction // J. Am. Heart Associat. 2017. N 6. P. e003989
6. Havmöller R., Chugh S.S. Plasma biomarkers for prediction of sudden cardiac death: another piece of the risk stratification puzzle? // Circ. Arrhythm. Electrophys. 2012 Feb. Vol. 5, N 1. P. 237-243.
7. Van Kimmenade R.R., Januzzi J.L.Jr. Emerging biomarkers in heart failure // Clin. Chem. 2012 Jan. Vol. 58, N 1. P. 127-138.
8. Ahmad T., Fiuzat M., Neely B. et. al. Biomarkers of Myocardial Stress and Fibrosis as Predictors of Mode of Death in Patients with Chronic Heart Failure // JACC Heart Fail. 2014 Jun. Vol. 2, N 3. P. 260-268.
9. Xie P., Cao Y.S., Su P. et al. Expression of toll-like receptor 4, tumor necrosis factor- alpha, matrix metalloproteinase-9 and effects of benazepril in patients with acute coronary syndromes // Clin. Med. Insights Cardiol. 2010. Vol. 4. P. 89-93.
10. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure // Eur. Heart J. 2016. Vol. 37. P. 2129-2200.
11. Huttin O., Coiro S., Selton-Suty Ch. et. al. Prediction of Left Ventricular Remodeling after a Myocardial Infarction: Role of Myocardial Deformation: A Systematic Review and Meta-Analysis // PLoS One. 2016. Vol. 11, N 12: e0168349.
12. Huang D., Cheng J.W.M. Pharmacologic Management of Heart Failure with Preserved Ejection Fraction // The Annals of Pharmacotherapy. 2010. Vol. 44, N 12. P. 1933-1945.
13. Ponikowski P., Voors A.A., Anker S.D. et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) - Developed with the special contribution of the Heart Failure Association (HFA) of the ESC // Eur. Heart J. 2016. Vol. 37. P. 2129-2200.
14. Sunil Nadar. New Classification for Heart Failure with Mildly Reduced Ejection Fraction // Sultan Qaboos Univ. Med. J. 2017 Feb. Vol. 17, N 1. P. 23-26.
15. Meijers W.C., van der Velde A.R., de Boer R.A. Biomarkers in heart failure with preserved ejection fraction // Neth Heart J. 2016 Apr. Vol. 24, N 4. P. 252-258.
16. Martinez-Rumayor A., Richards A.M., Burnett J.C., Januzzi J.L. Jr. Biology of the natriuretic peptides // Am. J. Cardiol. 2008 Feb 4. Vol. 101, N 3A. P. 3-8.
17. Lubien E., DeMaria A., Krishnaswamy P. et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings // Circulation. 2002. Vol. 105. P. 595-601.
18. Maisel A.S., McCord J., Nowak R.M. et al. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study // J. Am. Coll. Cardiol. 2003. Vol. 41. P. 2010-2017.
19. Mak G.S, DeMaria A., Clopton P., Maisel A.S. Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function: comparison with tissue Doppler imaging recordings // Am. Heart J. Vol. 2004, N 148. P. 895-902.
20. Tschope C., Kasner M., Westermann D. et al. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements // Eur. Heart J. 2005. Vol. 26. P. 2277-2284.
21. Iwanaga Y., Nishi I., Furuichi S. et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure // J. Am. Coll. Cardiol. 2006. Vol. 47. P. 742-748.
22. Yancy C.W., Jessup M., Bozkurt B. et al. ACCF/AHA Guideline for the Management of Heart Failure: a Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines // Circulation. 2013. Vol. 128: e240-e327.
23. de Boer R.A., Lok D.J., Jaarsma T. et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction // Ann. Med. 2011. Vol. 43. P. 60-68.
24. Carrasco-Sanchez F.J., Aramburu-Bodas O., Salamanca-Bautista P. et al. Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction // Int. J. Cardiol. 2013. Vol. 169. P. 177-182.
25. Edelmann F., Wachter R., Schmidt A.G. et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial // JAMA. 2013. Vol. 309. P. 781-791.
26. Edelmann F., Holzendorf V., Wachter R. et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial // Eur. J. Heart Fail. 2015. Vol. 17. P. 214-223.
27. Bayes-Genis A., Pascual-Figal D., Januzzi J.L. et. al. Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure // Rev. Esp. Cardiol. Vol. 63, N 10. P. 1171-1178.
28. Frioes F., Lourenco P., Laszczynska O. et al. Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction // Clin. Res. Cardiol. 2015. Vol. 104. P. 491-499.
29. Manzano-Fernandez S., Mueller T., Pascual-Figal D. et. al. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction // Am. J. Cardiol. 2011. Vol. 107. P. 259-267.
30. Johnson J.L. Matrix metalloproteinases and their inhibitors in cardiovascular pathologies: current knowledge and clinical potential. Metalloproteinases // In Medicine. 2014. Vol. 1. P. 21-36.
Review
For citations:
Pecherina T.B., Fedorova N.V., German A.I., Chernobay A.G., Solodilova T.P., Karetnikova V.N., Gruzdeva O.V., Polikutina O.M., Kashtalap V.V., Barbarash O.L. Clinical significance and dynamics of biomarkers of myocardial remodeling in patients with ST segment elevation myocardial infarction and preserved left ventricular function. Ateroscleroz. 2018;14(1):5-15. (In Russ.) https://doi.org/10.15372/ATER20180101